EMA suggests halt on Servier's Protelos; Harvard sacked ex-SAC manager for fraud; FDA approves Merck HIV drug for infants;

@FiercePharma: Best-read FiercePharma special yesterday: Top 10 Drug Patent Losses of 2014. Report | Follow @FiercePharma

@TracyStaton: Top FiercePharma news Thursday: Wanna trade? Novartis + Merck reportedly negotiating $5B unit swap. Story | Follow @TracyStaton

@EricPFierce: Genentech liquid Tamiflu delays stem from packaging issues. Shortages possible but capsules available. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: With CEO pick, Teva bets turnaround savvy will trump pharma know-how. Thursday's story | Follow @CarlyHFierce

> The EMA has recommended suspending sales of bone-building drug Protelos made by French drugmaker Servier because of blood clot and heart risks. Story

> Some doctors in the U.K. are suggesting that new drug payment guidelines will favor the young over the old and sick. More

> The FDA has approved a new formulation of Merck ($MRK) Isentress to treat infants and children with HIV infection. Report

> Dr. Reddy's Laboratories is launching anti-hypertension drug, Optidoz, in India. Report

> A group of U.S. Blue Cross insurers are creating the world's biggest provider network for international health-insurance customers. Story

Medical Device News

@FierceMedDev: St. Louis spinal/sports medicine co. ISTO Technologies names George Dunbar CEO. Release | Follow @FierceMedDev

@MichaelGFierce: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: How much is that artificial hip? Your doctor probably doesn't know. Story | Follow @EmilyWFierce

@MarkHFierce: Three heavy-hitters--Covidien, NEA and Lightstone--are jointly investing in a new Irish med tech company. Release | Follow @MarkHFierce

> PureTech's Tal Medical faces a clinical test of its rapid depression treatment. Editor's corner

> Endo finally ditches its urology tech business for up to $130M. More

> Inspire Medical's sleep apnea implant scores for majority in study. Story

Biotech News

@FierceBiotech: MannKind has an FDA advisory committee review of Afrezza set for April 1. Release | Follow @FierceBiotech

@JohnCFierce: 1 of today's top stories: Ex-$BMS R&D chief Sigal makes the leap into venture finance. Joins Mott at NEA. Story | Follow @JohnCFierce

@DamianFierce: Analyst says Lombard's U.S. IPO could come in at $70M. EP Vantage story | Follow @DamianFierce

@EmilyMFierce: Blast at San Francisco Amgen lab injures 2. Story | Follow @EmilyMFierce

> FDA reviewer flunks Chelsea's effort at a comeback for Northera. Story

> It's an industry tradition: Biopharma gets giddy as JPMorgan gets the party started. Article

> Amgen spinoff Atara cranks its Series B up to $52M. Report

And Finally... Ahead of the trial of a former SAC hedge fund manager for insider trading in pharma stocks, unsealed documents show he was kicked out of Harvard Law School for faking his grades. Story